Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib and Tislelizumab with mCapeOX in Rectal Cancer
NCT06443671Phase 3Not yet recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Jun 2024
- Primary completion
- Jun 2026
- Modality
- Fragment-Derived Small Molecules, Monoclonal Antibodies, Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 3 trial of fruquintinib, tislelizumab in rectal cancer, sponsored by Peking University Cancer Hospital & Institute. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
fruquintinibtislelizumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT06443671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06443671.